Gastric Carcinoma


Gastric carcinoma remains a common disease with a dismal prognosis. It represents the fourth most frequent malignancy and second leading cause of caner-related death worldwide. A signifi cant geographic variation exists with high-risk areas including Japan, Central and South America and Eastern Asia. Despite the major improvements in diagnosis and treatment, less than 20% of patients survive to 5 years. Chemotherapy and radiochemotherapy may be applied, but do not cure the disease. Thus, improvement of gastric cancer therapy will depend on novel therapeutic approaches.

Membrane-bound human epidermal growth factor receptors (HER), c-MET, and insulinlike grow

th factor 1 receptor (IGF-1R) mediated mitogenic signals have been implicated in gastric tumor growth in response to the extracellular ligands, such as epidermal growth factor (EGF), hepatocyte growth fact  or (HGF) and insulin growth factors (IGF), respectively. Clinical observations have also suggested that the organ environment can infl uence the tumor response to chemotherapy. Therefore, orthotopic implantation of human gastric cancer cells or tissues in nude mice is a more ideal model for evaluation of diff erent antitumor therapies for the gastric cancers.  

PharmaLegacy Models and research Tools

Case Study  -Inhibition of Tumor Growth